SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
acutelily
Lv3
290 积分
2024-04-15 加入
最近求助
最近应助
互助留言
Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United States
1天前
已完结
Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial
1天前
已完结
New treatment options for hormone receptor positive breast cancer in 2023
1天前
已完结
Ribociclib plus Endocrine Therapy in Early Breast Cancer
1天前
已完结
Addition of PI3K/AKT/mTOR inhibitors to fulvestrant for advanced HR+/HER2- breast cancer: a systematic review and meta-analysis
5天前
已完结
Synthesis of site‐specific Fab‐drug conjugates using ADP‐ribosyl cyclases
6天前
已完结
LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein
7天前
已完结
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells
7天前
已完结
Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR+ breast cancer patients undergoing CDK4/6 treatment
8天前
已完结
The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study
8天前
已完结
没有进行任何应助
感谢,点赞,速度真快
1天前
感谢,点赞,速度真快
1天前
感谢,点赞,速度真快
1天前
感谢,点赞,速度真快
1天前
已经不需要了【积分已退回】
4天前
感谢,点赞,速度真快
5天前
感谢,点赞,速度真快
6天前
感谢,点赞,速度真快
7天前
感谢,速度真快
7天前
感谢,点赞,速度真快
7天前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论